Where are we with postmenopausal hormone therapy in 2005?

Gynecol Endocrinol. 2005 Nov;21(5):248-56. doi: 10.1080/09513590500279733.

Abstract

Recently, two large randomized placebo-controlled studies on long-term postmenopausal hormone replacement therapy, the Heart and Estrogen/progestin Replacement Study (HERS) and the Women's Health Initiative (WHI), have raise a lot of controversies, especially on the cardiovascular aspects. We briefly review these two trials and discuss what we know and do not know about postmenopausal hormone therapy, including the evidence on novel choices such as raloxifene and tibolone.

Publication types

  • Review

MeSH terms

  • Aged
  • Breast Neoplasms / epidemiology
  • Colonic Neoplasms / epidemiology
  • Coronary Disease / epidemiology
  • Coronary Disease / etiology
  • Coronary Disease / prevention & control
  • Dementia / prevention & control
  • Endometrial Neoplasms / epidemiology
  • Estrogen Replacement Therapy / adverse effects*
  • Estrogen Replacement Therapy / trends*
  • Female
  • Hip Fractures / epidemiology
  • Hip Fractures / prevention & control
  • Humans
  • Middle Aged
  • Neoplasms / epidemiology
  • Placebos
  • Postmenopause*
  • Progestins / administration & dosage
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Stroke / epidemiology
  • Venous Thrombosis / epidemiology
  • Women's Health

Substances

  • Placebos
  • Progestins